21-position Substituted Patents (Class 514/181)
-
Publication number: 20120225853Abstract: The treatment and/or prevention of depression by the co-administration of an estrogen with the progestin dienogest for HRT and/or contraception.Type: ApplicationFiled: March 2, 2012Publication date: September 6, 2012Applicant: BAYER PHARMA AGInventors: Ina RUDOLPH, Thomas GRÄSER
-
Publication number: 20120177739Abstract: A tablet comprising a core containing an active agent, and a coating, the core being disposed within the coating such that the coating has a thickness about a longitudinal axis (X-Y) of about 4.85 to 4.95 mm. The position of the core within the coating dictating that the active agent is released rapidly after a lag time during which time no active agent is released.Type: ApplicationFiled: March 23, 2012Publication date: July 12, 2012Applicant: Jagotec AGInventors: Guy Vergnault, Pascal Grenier, Christophe Dragan
-
Publication number: 20120172344Abstract: Provided is an insulin-producing cell inducer, an enhancer for glucose intake of muscles, and a therapeutic agent for diabetes or diabetes complications, wherein an active ingredient of those provided is an estrogenic compound such as estrogen and estradiol. With the present invention, functions of insulin-producing cells can be recovered since the insulin-producing cells are induced in pancreatic ducts, and blood glucose level can be immediately lowered since glucose in the blood can be effectively taken up by muscles; therefore, diabetes and diabetes complications can be prevented or treated.Type: ApplicationFiled: July 16, 2010Publication date: July 5, 2012Applicant: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATIONInventor: Akari Inada
-
Publication number: 20120142655Abstract: The present invention relates to novel crystalline Form II of 17?-acetoxy-21-methoxy-11?-[4-N,N-dimethylaminophenyl]-19-norpregna-4,9-diene-3,20-dione, (also known as CDB-4124), processes for the preparation thereof and pharmaceutical compositions comprising it. Form II can be crystallized from different medium such as esters of C1-C4 alcohols and carboxylic acids, ketones, cyclohexane, acetonitrile, dimethylformamide, dimethyl sulfoxide, water and any mixture thereof.Type: ApplicationFiled: August 5, 2010Publication date: June 7, 2012Inventors: Attila Balázs, János Csörgei, Ádám Demeter, Csaba Sánta
-
Publication number: 20120129823Abstract: A method for hormonal contraception comprising administering at least one contraceptive hormone in a plurality of linked taking periods optionally having a sequence lasting several years. Each taking period comprises at least one taking cycle. Each taking cycle comprises a duration-constant taking phase lasting several days and a taking pause lasting several days. In each taking phase the hormonal component is administrated in a daily unit. In each taking pause either a placebo or no unit is administered. The duration of the taking phase or phases of at least the final taking period is at least 22 days. The duration of each taking phase in any taking period preceding a following taking period is shorter than that in each of the taking phases in each following taking period.Type: ApplicationFiled: December 12, 2011Publication date: May 24, 2012Inventor: Hermann KULMANN
-
Patent number: 8163725Abstract: Improved topical gel compositions for the treatment of skin disorders are described. The gel compositions contain carbomer and methylparaben, and are substantially free of methylparaben crystalline particles after an extended period of storage.Type: GrantFiled: September 22, 2011Date of Patent: April 24, 2012Assignee: Galderma R&D SNCInventors: Jean-Christophe Buge, Karine Nadau-Fourcade, Cyril Meunier
-
Publication number: 20120077777Abstract: The present invention relates to a compound of following formula (I): or to a pharmaceutically acceptable salt thereof, as well as to pharmaceutical compositions including same and to the use thereof as a drug, in particular for treating a proliferative disease such as cancer.Type: ApplicationFiled: May 20, 2010Publication date: March 29, 2012Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), PIERRE FABRE MEDICAMENTInventors: Christophe Long, Yves Guminski, Fadila Derguini, Joséphine Beck, Frédéric Cantagrel
-
Patent number: 8124597Abstract: Therapeutic compositions and methods for treatment of late-onset Gaucher disease are described herein. The compositions comprise compounds having activity as pharmacological chaperones for mutant forms of the beta-glucocerebrosidase. Methods of treatment involve providing therapeutically effective amounts of such compositions to subjects in need thereof.Type: GrantFiled: August 22, 2008Date of Patent: February 28, 2012Assignees: The Hospital for Sick Children, McMaster UniversityInventors: Don J. Mahuran, Michael B. Tropak, Justin D. Buttner, Jan E. Blanchard, Eric D. Brown
-
Patent number: 8119619Abstract: Steroid compounds possessing a hydrogen donor in 3beta position, either in the form of a hydroxy- or a sulfate group, function as efficient blockers of the 3alpha-hydroxy-pregnan-steroid action and thus have utility as therapeutic substances for the prevention and/or treatment of steroid related CNS disorders. Treatment methods based on the administration of these substances are disclosed, and these substances either alone or in combination are also suggested for the manufacture of pharmaceuticals for the treatment of many specific steroid induced CNS disorders.Type: GrantFiled: January 7, 2011Date of Patent: February 21, 2012Assignee: Umecrine ABInventors: Torbjörn Bäckström, Per Lundgren, Ming-De Wang, Inga-Maj Johansson
-
Publication number: 20120003306Abstract: The invention discloses a pharmaceutical composition of bioactive nanoparticles composed of chitosan, poly-glutamic acid, and a bioactive agent for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.Type: ApplicationFiled: September 8, 2011Publication date: January 5, 2012Inventors: Hsing-Wen Sung, Kiran Sonaje, Hosheng Tu
-
Patent number: 8080263Abstract: Stabilized dispersions are provided for the delivery of a bioactive agent. The dispersions preferably comprise a plurality of perforated microstructures dispersed in a suspension medium that typically comprises a liquid fluorochemical. As density variations between the suspended particles and suspension medium are minimized and attractive forces between microstructures are attenuated, the disclosed dispersions are particularly resistant to degradation, such as by settling or flocculation. In particularly preferred embodiments the stabilized dispersions may be directly administered to the lung of a patient using an endotracheal tube or bronchoscope.Type: GrantFiled: May 27, 2008Date of Patent: December 20, 2011Assignee: Novartis AGInventors: Luis A. Dellamary, Thomas E. Tarara, Alexey Kabalnov, Jeffry G. Weers, Ernest G. Schutt
-
Publication number: 20110306564Abstract: In a dissolving step, in a container 13, a poorly soluble drug and a dispersion stabilizer (polyvinylpyrrolidone and sodium lauryl sulfate) are dissolved in a volatile organic solvent. In a solid composition forming step following the dissolving step, the organic solvent contained in the solution is removed by evaporation, and by the organic solvent removal, a solid composition 1 is obtained as a residue, and the solid composition 1 becomes fixed on the inner wall of the container 13. In a water injecting step following the solid composition forming step, water 2 is injected into the interior of the container 13. In a microparticle dispersion liquid preparing step following the water injecting step, laser light L emitted from a laser light source 11 is irradiated on the solid composition 1 fixed on the inner wall of the container 13 and optical energy is thereby applied to the solid composition 1.Type: ApplicationFiled: August 25, 2011Publication date: December 15, 2011Inventors: Gen Takebe, Mitsuo Hiramatsu, Tokio Takagi
-
Publication number: 20110286927Abstract: In one aspect, the invention relates to a method for identifying a drug candidate with activity as a neuroprotective agent. The method includes determining whether a compound reduces ATF4 activity; and identifying the compound that reduces ATF4 activity as a drug candidate.Type: ApplicationFiled: August 4, 2008Publication date: November 24, 2011Applicant: CORNELL UNIVERSITYInventor: Rajiv R. Ratan
-
Publication number: 20110287112Abstract: A prostate cancer progression inhibitor comprises 4-(4-cyano-2-{[2-(4-fluoro-1-naphthyl)propanoyl]amino}phenyl)butyric acid, a salt thereof, a solvate thereof, or a prodrug thereof. 4-(4-Cyano-2-{[2-(4-fluoro-1-naphthyl)propanoyl]amino}phenyl)butyric acid is useful as a prostate cancer progression inhibitor because this butyric acid has, for example, a growth inhibiting effect and a hormone responsiveness recovering effect on prostate cancer that has acquired hormone resistance.Type: ApplicationFiled: January 29, 2010Publication date: November 24, 2011Applicants: ONO PHARMACEUTICAL CO., LTD., KYOTO UNIVERSITYInventors: Osamu Ogawa, Gozoh Tsujimoto, Eijiro Nakamura, Tomomi Kamba, Yosuke Shimizu, Naoki Terada, Toshiya Kanaji, Takayuki Maruyama
-
Patent number: 8053427Abstract: Improved topical gel compositions, such as those containing brimonidine, for the treatment of skin disorders are described. The gel compositions contain carbomer and methylparaben, and are substantially free of methylparaben crystalline particles after an extended period of storage.Type: GrantFiled: June 13, 2011Date of Patent: November 8, 2011Assignee: Galderma R&D SNCInventors: Jean-Christophe Buge, Karine Nadau-Fourcade, Cyril Meunier
-
Publication number: 20110262543Abstract: Carrier particles for dry powder formulations for inhalation having reduced electrostatic charges are prepared.Type: ApplicationFiled: April 21, 2011Publication date: October 27, 2011Applicant: Chiesi Farmaceutici S.p.A.Inventors: Daniela Cocconi, Rossella Musa
-
Publication number: 20110263554Abstract: The invention provides methods to identify agents useful to prevent, inhibit or treat viral infections, e.g. filovirus infections, as well as compositions having one or more agents to prevent, inhibit or treat viral infection.Type: ApplicationFiled: November 6, 2009Publication date: October 27, 2011Applicant: WARF - Wisconsin Alumni Research FoundationInventors: Yoshihiro Kawaoka, Shinji Watanabe, Yasuko Hatta
-
Publication number: 20110244017Abstract: The present invention provides an absorbable coating for an implantable device and the methods of making and using the same.Type: ApplicationFiled: March 31, 2010Publication date: October 6, 2011Applicant: ABBOTT CARDIOVASCULAR SYSTEMS INC.Inventors: Lothar W. Kleiner, Syed F.A. Hossainy, Mikael Trollsas, Stephen D. Pacetti
-
Patent number: 8003127Abstract: Compositions comprising a nanoparticulate corticosteroid and an antihistamine are described. The compositions are useful in the prophylaxis and chronic treatment of asthma in adults and pediatric patients and for the relief of allergic conjunctivitis, symptoms of seasonal allergic rhinitis in adults and pediatric patients. Combining an antihistamine with a nanoparticulate corticosteroid in a single formulation results in improved efficacy.Type: GrantFiled: March 23, 2006Date of Patent: August 23, 2011Assignee: Elan Pharma International LimitedInventors: Gary Liversidge, Scott Jenkins, H. William Bosch, Christian F. Wertz
-
Publication number: 20110189175Abstract: Provided herein are methods for identifying a subject afflicted with chronic lymphocytic leukemia who is responsive to treatment with a chemotherapeutic agent by detecting the presence or absence of at least one APOE4 allele in the subject, the presence of an APOE4 allele identifying the subject as responsive to the treatment. Also provided are methods of treating a subject afflicted with chronic lymphocytic leukemia, including administering an estrogenic agent, an androgen withdrawal agent, an apoE4 peptide or mimetic thereof, and/or a chemotherapeutic agent in an amount effective to treat said chronic lymphocytic leukemia. Methods of determining a prognosis for a patient diagnosed with chronic lymphocytic leukemia are also provided. In addition, methods for stratifying a subject into a subgroup of a clinical trial and methods for identifying a patient in a clinical trial of a treatment for chronic lymphocytic leukemia are herein provided.Type: ApplicationFiled: January 20, 2011Publication date: August 4, 2011Inventors: J. Brice Weinberg, Warren J. Strittmatter
-
Publication number: 20110182828Abstract: The present invention provides compounds of Formula (I), and pharmaceutically acceptable salts, solvates, esters, prodrugs, tautomers, or isomers of said compounds), having the general structure: wherein L, R1, R2, R3, R4, R5, and R6 are selected independently of each other and as defined herein. The present invention also provides compounds (and salts, solvates, esters, prodrugs, tautomers, and isomers) of Formulas II, III, IV, V, and VI, as defined herein. Also provided are pharmaceutical compositions, methods of preparing, and methods of using such compounds in the treatment and prophylaxis of a wide range of immune, autoimmune, and inflammatory diseases and conditions.Type: ApplicationFiled: December 18, 2008Publication date: July 28, 2011Applicant: Schering CorporationInventors: John C. Anthes, Kevin D. Mccormick, John A. Hey, Robert G. Aslanian, Purakkattle J. Biju, Michael Y. Berlin, Daniel M. Solomon, Phillippa H. Solomon, Hongwu Yang, Yeon-Hee Lim, Yoon Joo Lee, Rema Danielle Bitar
-
Publication number: 20110165259Abstract: [Problem to be Solved] The purpose of present invention is to provide a medicine which has low contamination with a fine-pulverizing medium, is safe and has improved bioavailability. [Solution] A method for producing a composite organic compound powder for medical use is used which comprises: mixing a poorly water-soluble and crystalline organic compound powder, a physiologically acceptable salt, a physiologically acceptable polyol, and a carboxyvinyl polymer and fine-pulverizing the organic compound powder; and removing at least the salt and the polyol during or after fine-pulverizing.Type: ApplicationFiled: September 15, 2009Publication date: July 7, 2011Applicant: ACTIVUS PHARMA CO., LTD.Inventors: Takashi Hirokawa, Takahiro Tada, Jun Nihira
-
Publication number: 20110150775Abstract: The present invention provides systems for developing and/or testing therapies for prenatal diseases and conditions including Down Syndrome. The present invention also provides diagnostic methods for Down Syndrome involving, in some embodiments, gene expression analyses of fetal RNA and/or detection of expression of particular genes involved in Down Syndrome. Also provided are microarrays and kits useful in prenatal diagnostic applications.Type: ApplicationFiled: June 1, 2009Publication date: June 23, 2011Inventors: Donna Slonim, Kirby Johnson, Diana Bianchi
-
Patent number: 7960367Abstract: Steroid compounds processing a hydrogen donor in 3beta position, either in the form of a hydroxy- or a sulfate group, function as efficient blockers of the 3alpha-hydroxy-pregnan-steroid action and thus have utility as therapeutic substances for the prevention and/or treatment of steroid related CNS disorders. Treatment methods based on the administration of these substances are disclosed, and these substances either alone or in combination are also suggested for the manufacture of pharmaceuticals for the treatment of many specific steroid induced CNS disorders.Type: GrantFiled: December 20, 2002Date of Patent: June 14, 2011Assignee: Umecrine ABInventors: Torbjorn Backstrom, Per Lundgren, Ming-De Wang, Inga-Maj Johansson
-
Publication number: 20110065637Abstract: A first embodiment can be a method to reduce SLOSH energy absorption within an organism by reducing the inelastic collisions. A fluid containing organism can utilize an embodiment of the method wherein one or more of reversibly increasing pressure within the organs or cells, reversibly increasing the volume within the organs or cells, reversibly altering vascular, molecular, or cell wall stiffness, or reversibly altering vascular, molecular, or cell wall configuration within said organism may reduce these collisions.Type: ApplicationFiled: September 10, 2010Publication date: March 17, 2011Inventor: David William Smith
-
Patent number: 7888340Abstract: Steroid compounds processing a hydrogen donor in 3beta position, either in the form of a hydroxy- or a sulfate group, function as efficient blockers of the 3alpha-hydroxy-pregnan-steroid action and thus have utility as therapeutic substances for the prevention and/or treatment of steroid related CNS disorders. Treatment methods based on the administration of these substances are disclosed, and these substances either alone or in combination are also suggested for the manufacture of pharmaceuticals for the treatment of many specific steroid induced CNS disorders.Type: GrantFiled: December 20, 2002Date of Patent: February 15, 2011Assignee: Umecrine ABInventors: Torbjorn Backstrom, Per Lundgren, Ming-De Wang, Inga-Maj Johansson
-
Publication number: 20110033468Abstract: An ophthalmic drug delivery system that contains phospholipid and cholesterol for prolonging drug lifetime in the eyes.Type: ApplicationFiled: August 10, 2009Publication date: February 10, 2011Applicant: Taiwan Liposome Co., LtdInventors: Sheue-Fang Shih, Po-Chun Chang, Yun-Long Tseng, Luke S.S. Guo, Keelung Hong
-
Publication number: 20110033561Abstract: For reducing the negative effects of the metabolic syndrome on mammal organisms, it is proposed to use phytoecdysones for diminishing the fat body mass in individuals, notably with a weight excess. Phytoecdysones are advantageously incorporated into a food composition. The phytoecdysones can come from food plants, such as quinoa.Type: ApplicationFiled: November 19, 2008Publication date: February 10, 2011Applicants: INSTITUT BIOPHYTIS SAS, UNIVERSITE PIERRE ET MARIE CURIEInventors: Stanislas Veillet, Rene Lafont
-
Publication number: 20110027369Abstract: The invention relates to a pharmaceutical composition in the form of a hydrogel that comprises a carboxylic acid diester, a C2-C4 alkyl alcohol, an active ingredient and a polymer matrix. The invention also relates to the use of a carboxylic acid diester as a transdermal permeation enhancer for an active ingredient in a pharmaceutical composition in the form of a hydrogel, whereby the composition comprises a polymer matrix and a C2-C4 alkyl alcohol. The invention also relates to a sweat-resistant composition in the form of a hydrogel, which comprises an acrylic polymer in combination with a cellulose derivative.Type: ApplicationFiled: August 18, 2010Publication date: February 3, 2011Inventor: Patrick FRANKE
-
Publication number: 20110002851Abstract: The present invention relates to the use of cationic colloidal compositions for the targeted delivery of an active compound to an inflammatory site or an activated vascular site for the preparation of a medicament for the treatment of MS and in general for all CNS or PNS inflammatory neurodegenerative and demyelinating diseases and for diagnostic applications of such compositions.Type: ApplicationFiled: October 31, 2007Publication date: January 6, 2011Applicant: MediGene AGInventors: Heinrich Haas, Paolo Riccio
-
Patent number: 7858606Abstract: The present invention relates to the use of a compound of formula (I), or a pharmaceutically acceptable salt, crystal form, complex, hydrate, or hydrolysable ester thereof, in the preparation of a medicament for treating a patient suffering from leukaemia, cancer or other proliferative disorder. A further embodiment relates to the use a compound of formula (I) in an assay for detecting the phosphorylation state of cellular substrates. The present invention also relates to novel compounds of formula (I), and the chemical synthesis thereof.Type: GrantFiled: May 23, 2001Date of Patent: December 28, 2010Assignees: Univerzita Palackeho v Olomouci, Univerzita Karlova V PrazeInventors: Marian Hajduch, Jan Sarek
-
Publication number: 20100292198Abstract: A method of contraception is provided which involves delivery of 21 to 27 consecutive days of a progestin in the absence of an estrogen or other steroidal compound, followed by 1 to 7 days without an effective amount of an active agent. Also described is a pharmaceutically useful kit to facilitate delivery of this regimen.Type: ApplicationFiled: May 3, 2010Publication date: November 18, 2010Applicant: Wyeth LLCInventors: GARY SONDERMANN GRUBB, GINGER DALE CONSTANTINE
-
Publication number: 20100234334Abstract: The invention relates to nitrooxyderivative of corticosteriods of general formula (I) and pharmaceutical acceptable salts or stereoisomers thereof wherein R is the corticosteriod residue of formulas (II): The compounds are useful in the treatment of respiratory diseases, inflammatory diseases, dermatological disease and ocular diseases.Type: ApplicationFiled: January 28, 2008Publication date: September 16, 2010Applicant: NICOX S.A.Inventors: Francesca Benedini, Stefano Biondi, Ennio Ongini
-
Patent number: 7790145Abstract: A respiratory dispersion is provided for the pulmonary delivery of at least two bioactive agents. The dispersion comprises a propellant suspension medium having dispersed therein a plurality of perforated microstructures, wherein the two bioactive agents are incorporated into individual perforated microstructures.Type: GrantFiled: February 5, 2008Date of Patent: September 7, 2010Assignee: Novartis AGInventors: Jeffry G. Weers, Ernest G. Schutt, Luis A. Dellamary, Thomas E. Tarara, Alexey Kabalnov
-
Publication number: 20100221351Abstract: In accordance with certain embodiments of the present disclosure, A method for intracellular delivery of cytotoxin in combination with cyoablation is provided. The method includes encapsulation of one or more cytotoxins in a thermally responsive nanocapsule by decreasing the temperature of the nanocapsule to increase the permeability of the nanocapsule whereby the one or more cytotoxins are sucked into or diffuse into the nanocapsule. The temperature of the nanocapsule is increased and the nanocapsule is delivered into a cell. Cryoablation is performed in proximity to the cell resulting in the release of the one or more cytotoxins from the nanocapsule into the cell.Type: ApplicationFiled: March 1, 2010Publication date: September 2, 2010Applicant: UNIVERSITY OF SOUTH CAROLINAInventor: Xiaoming He
-
SPINAL CORD INJURY, INFLAMMATION, AND IMMUNE-DISEASE: LOCAL CONTROLLED RELEASE OF THERAPEUTIC AGENTS
Publication number: 20100196481Abstract: A drug delivery system is provided for treatment of oxidative stress. The drug delivery system can include a therapeutic agent and a matrix. The therapeutic agent can include an antioxidant or steroid. The matrix can include a hydrogel, particle, microparticle, or nanoparticle. A method of treating injury, including peripheral nerve injury or spinal cord injury, is also provided. The method includes injecting the drug delivery system at the site of injury.Type: ApplicationFiled: September 25, 2009Publication date: August 5, 2010Applicant: INVIVO THERAPEUTICS CORPORATIONInventors: Christopher D. Pritchard, Robert S. Langer, Francis M. Reynolds, Eric J. Woodard -
Publication number: 20100159014Abstract: Polymeric micellar clusters formed from amphiphilic carbohydrate polymers and their uses in formulating drugs is disclosed, and in particular the finding that amphiphilic carbohydrate polymers are capable of self assembling to form micellar clusters in which the carbohydrate amphiphiles aggregate into hierarchically organised micellar clusters of individual aggregates. The micellar clusters may be transformed into stable nanoparticles with drugs, especially hydrophobic drugs that have poor aqueous solubility, and may improve the transfer of hydrophobic drugs across biological barriers.Type: ApplicationFiled: August 8, 2007Publication date: June 24, 2010Inventors: Igeoma F. Uchegbu, Andreas G. Schatzlein, Xueliang Hou
-
Publication number: 20100137271Abstract: Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs are provided. The pharmaceutical compositions include a therapeutically effective amount of a hydrophobic drug, preferably a steroid; a solubilizer, and a surfactant. The synergistic effect between the hydrophobic drug and the solubilizer results in a pharmaceutical formulation with improved dispersion of both the active agent and the solubilizer. As a result of the improved dispersion, the pharmaceutical composition has improved bioavailability upon administration. Methods of improving the bioavailability of hydrophobic drugs administered to a patient are also provided.Type: ApplicationFiled: November 24, 2009Publication date: June 3, 2010Applicant: LIPOCINE, INC.Inventors: FENG-JING CHEN, MAHESH V. PATEL, DAVID T. FIKSTAD, HUIPING ZHANG, CHANDRASHEKAR GILIYAR
-
Publication number: 20100130461Abstract: A topical composition for treatment of contact dermatitis comprising a corticosteroid, one or more drying agents, such as zinc oxide and talc, an alcohol solvent, a humectant and a viscosity agent, such as bentonite. The humectant may be glycerin, and the carrier is water.Type: ApplicationFiled: January 26, 2010Publication date: May 27, 2010Inventor: Bruce Burkenstock, SR.
-
Patent number: 7718640Abstract: The present invention relates to pharmaceutical compositions, formulated for injectable administration, which comprises a testosterone ester, in particularly testosterone undecanoate, in a vehicle comprising castor oil and a co-solvent. Upon injecting the compositions according to a particular administration scheme, reliable levels of testosterone in serum in the normal physiological range is achieved for a long period. This allows for the use of the compositions in hormone replacement therapy and male contraception without concomitant monitoring of testosterone levels in serum by a physician.Type: GrantFiled: March 12, 2004Date of Patent: May 18, 2010Assignee: Bayer-Schering Pharma AGInventors: Doris Hubler, Sabine Fricke, Jan-Peter Ingwersen, Wilhelm Kuhnz
-
Publication number: 20100120737Abstract: The present invention relates to amorphous ciclesonide, methods to prepare the same, pharmaceutical compositions comprising amorphous ciclesonide as active ingredient, and methods of treatment using amorphous ciclesonide.Type: ApplicationFiled: November 10, 2008Publication date: May 13, 2010Inventors: Martin Feth, Rolf-Peter Hummel, Jurgen Volz, Peter Zimmermann, Beate Schmidt
-
Publication number: 20100105641Abstract: The subject invention provides a liquid contraceptive formulation for oral transmucosal administration. The formulation comprises etonogestrel, optionally together with ethinyl estradiol but does not contain a matrix former or a percutaneous absorption promoter, which is a hydroxy acid or a salt thereof.Type: ApplicationFiled: December 11, 2007Publication date: April 29, 2010Inventor: Kees Van Der Voort Maarschalk
-
Publication number: 20100093685Abstract: The invention relates to nitrooxyderivative of corticosteroids of general formula (I) and pharmaceutically acceptable salts or stereoisomers thereof R-(Z)a-Rx??(I) wherein R is the corticosteroid residue of formula (II): wherein: R1 is OH, R2—CH3, or R1 and R2 are taken together to form a group of formula (III) R3 is Cl or F; R4 is H or F; wherein R1, R2, R3 and R4 can be linked to the correspondent carbon atoms of the steroidal structure in position ? or ?; with the proviso that: when R1 and R2 are the group of formula (III) then R3 is F and R4 is H or F; The compounds are useful in the treatment of respiratory diseases, inflammatory diseases, dermatological diseases and ocular diseases.Type: ApplicationFiled: January 28, 2008Publication date: April 15, 2010Inventors: Francesca Benedini, Stefano Biondi, Ennio Ongini
-
Publication number: 20100087413Abstract: The present invention relates to the use of an 11-?-HSD-type 1 and or type 2 inhibitor for the manufacture of a pharmaceutical agent for the prevention and/or treatment of inflammation-induced and/or immune-mediated loss of bone and/or cartilage.Type: ApplicationFiled: September 21, 2004Publication date: April 8, 2010Inventor: Thomas Wilckens
-
Publication number: 20090320845Abstract: Methods for easing the duration of pain experienced by patients during a cluster headache are disclosed including providing a high-pressure source of substantially pure oxygen, applying the oxygen to the patient so that inhalation by the patient is substantially limited to inhalation of the substantially pure oxygen, inhaling the substantially pure oxygen in order to cause hyperventilation by the patient, and continuing hyperventilation at least until the patient achieves respiratory alkalosis, hypocapnia hyperoxia, and until the pain is terminated. The method preferably includes using a demand valve having a predetermined manual purge flow rate and a variable output flow rate to the user based on respiratory demand.Type: ApplicationFiled: June 30, 2008Publication date: December 31, 2009Applicant: Linde AGInventors: Royce S. Fishman, Peter L. Batcheller, Michael Berger
-
Patent number: 7628978Abstract: Stabilized dispersions are provided for the delivery of a bioactive agent to the respiratory tract of a patient. The dispersions preferably comprise a plurality of perforated microstructures dispersed in a suspension medium that typically comprises a hydrofluoroalkane propellant. As density variations between the suspended particles and suspension medium are minimized and attractive forces between microstructures are attenuated, the disclosed dispersions are particularly resistant to degradation, such as, by settling or flocculation. In particularly preferred embodiments, the stabilized dispersions may be administered to the lung of a patient using a metered dose inhaler.Type: GrantFiled: August 19, 2003Date of Patent: December 8, 2009Assignee: Novartis Pharma AGInventors: Jeffry G. Weers, Ernest G. Schutt, Luis Dellamary, Thomas E. Tarara, Alexey Kabalnov
-
Publication number: 20090297619Abstract: Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the agent following administration. The novel compositions release the agent following administration for a time period ranging from about 2 to about 24 hours or longer.Type: ApplicationFiled: June 11, 2009Publication date: December 3, 2009Inventors: Jon Swanson, Rajeev A. Jain, Robert Hontz, John G. Devane, Kenneth Iain Cumming, Maurice Joseph Anthony Clancy, Janet Elizabeth Codd, Gary G. Liversidge
-
Publication number: 20090258849Abstract: The invention relates to new steroids nitrooxyderivatives, to topical pharmaceutical formulations thereof, and their use for treating skin or mucosal membrane diseases or disorders. These new steroids nitrooxyderivatives have an improved pharmacological activity and enhanced local tolerability.Type: ApplicationFiled: June 26, 2009Publication date: October 15, 2009Applicants: Ferrer Internacional S.A.Inventors: Francesca BENEDINI, Ennio Ongini, Antonio Guglietta, Daniel Palop, Marta Princep
-
Publication number: 20090247496Abstract: The present invention discloses a novel use of a lanostane having the following formula (I) in enhancing uptake of nutrients: wherein R1 is either H or CH3; R2 is OCOCH3, ?O or OH; R3 is H or OH; R4 is —C(?CH2)—C(CH3)2Ra, in which Ra is H or OH, or —CH?C(CH3)—Rb, in which Rb is CH3 or CH2OH; R5 is H or OH; and R6 is CH3 or CH2OH.Type: ApplicationFiled: March 31, 2009Publication date: October 1, 2009Applicant: Sinphar Pharmaceutical Co., Ltd.Inventors: Hang-Ching Lin, Tsu-Chung Chang, Wen-Liang Chang, Yi-Yang Song
-
Patent number: 7566705Abstract: A medicament containing, separately or together, (A) formoterol or a pharmaceutically acceptable salt thereof or a solvate of formoterol or a solvate of the salt and (B) mometasone furoate, for simultaneous, sequential or separate administration in the treatment of an inflammatory or obstructive airways disease.Type: GrantFiled: August 8, 2005Date of Patent: July 28, 2009Assignee: Novartis AGInventors: Ian F Hassan, Jeremy G Clarke, Henry L Danahay